![]() |
|
|
CARDIOVASCULAR
Department of Physiology, Ulsan University College of Medicine, Seoul, South Korea (Ha.C.); Departments of Pharmacology (Y.-K.L. Y.-T.L., J.-H.K., S.-W.C., Y.-G.K.), Anesthesiology (Hu.C., S.-H.K.), Pediatrics (C.-U.J. and M.-H.K.), and Thoracic and Cardiovascular Surgery (G.-S.K.), and Institute of Cardiovascular Research (S.-W.C., Y.-G.K.), Chonbuk National University Medical School, Chonju, South Korea; and Departments of Pharmacology, Woosuk University College of Pharmacy, Wanju, South Korea (J.-S.E.)
Papaverine, 1-[(3,4-dimethoxyphenyl)methyl]-6,-7-dimethoxyisoquinoline, has been used as a vasodilator agent and a therapeutic agent for cerebral vasospasm, renal colic, and penile impotence. We examined the effects of papaverine on a rapidly activating delayed rectifier K+ channel (hKv1.5) cloned from human heart and stably expressed in Ltk cells as well as a corresponding K+ current (the ultrarapid delayed rectifier, IKur) in human atrial myocytes. Using the whole cell configuration of the patch-clamp technique, we found that papaverine inhibited hKv1.5 current in a time-and voltage-dependent manner with an IC50 value of 43.4 µM at +60 mV. Papaverine accelerated the kinetics of the channel inactivation, suggesting the blockade of open channels. Papaverine (100 µM) also blocked IKur in human atrial myocytes. These results indicate that papaverine blocks hKv1.5 channels and native hKv1.5 channels in a concentration-, voltage-, state-, and time-dependent manner. This interaction suggests that papaverine could alter cardiac excitability in vivo.
Address correspondence to: Dr. Yong-Geun Kwak, Department of Pharmacology, Chonbuk National University Medical School, Chonju, Chonbuk 561-180, South Korea. E-mail: ygkwak{at}moak.chonbuk.ac.kr
This article has been cited by other articles:
![]() |
B. H. Choi, J.-A. Park, K.-R. Kim, G.-I. Lee, Y.-T. Lee, H. Choe, S.-H. Ko, M.-H. Kim, Y.-H. Seo, and Y.-G. Kwak Direct block of cloned hKv1.5 channel by cytochalasins, actin-disrupting agents Am J Physiol Cell Physiol, August 1, 2005; 289(2): C425 - C436. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF] |
||||